Switch studies in virologically suppressed patients

Switch to RAL-containing regimen
Montreal Study : Switch ENF to RAL
Original article : J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):362-4 – A Talbot
Last update : 28/03/2014

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • Pilot, open-label retrospective study
  • 28 adults on salvage therapy with enfuvirtide-based regimen and HIV-1 RNA < 50 c/mL
  • Switch of enfuvirtide to RAL 400 mg bid, the remainder of the salvage regimen being unchanged. At the time of the switch:
    • ENF had been administered for a median of 25 months
    • Salvage regimen: 1 PI/r, N = 27, 1 NNRTI, N = 6
  • Follow-up of 6 months available for 27/28 patients
    • 26 maintained HIV-1 RNA < 50 c/mL
    • 1 single blip at 56 c/mL at W24
    • No significant changes in the CD4 counts
    • ENF-related injection site reactions resolved in all patients
    • RAL was well tolerated

 

 

Back to Table of Contents

Copyright AEI 2017 | Links | Contact | Faculty and Disclosure | Terms of use aei